264 related articles for article (PubMed ID: 36509553)
21. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.
Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS
Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic Cancer: A Review.
Park W; Chawla A; O'Reilly EM
JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082
[TBL] [Abstract][Full Text] [Related]
23. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
24. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
25. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
[TBL] [Abstract][Full Text] [Related]
26. Vascular Resections for Pancreatic Ductal Adenocarcinoma: Vascular Resections for PDAC.
Oba A; Bao QR; Barnett CC; Al-Musawi MH; Croce C; Schulick RD; Del Chiaro M
Scand J Surg; 2020 Mar; 109(1):18-28. PubMed ID: 31960765
[TBL] [Abstract][Full Text] [Related]
27. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
28. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
[TBL] [Abstract][Full Text] [Related]
29. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
[TBL] [Abstract][Full Text] [Related]
30. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer.
Boggi U; Kauffmann E; Napoli N; Barreto SG; Besselink MG; Fusai GK; Hackert T; Abu Hilal M; Marchegiani G; Salvia R; Shrikhande SV; Truty M; Werner J; Wolfgang CL; Bannone E; Capretti G; Cattelani A; Coppola A; Cucchetti A; De Sio D; Di Dato A; Di Meo G; Fiorillo C; Gianfaldoni C; Ginesini M; Hidalgo Salinas C; Lai Q; Miccoli M; Montorsi R; Pagnanelli M; Poli A; Ricci C; Sucameli F; Tamburrino D; Viti V; Addeo PF; Alfieri S; Bachellier P; Baiocchi GL; Balzano G; Barbarello L; Brolese A; Busquets J; Butturini G; Caniglia F; Caputo D; Casadei R; Chunhua X; Colangelo E; Coratti A; Costa F; Crafa F; Dalla Valle R; De Carlis L; de Wilde RF; Del Chiaro M; Di Benedetto F; Di Sebastiano P; Dokmak S; Hogg M; Egorov VI; Ercolani G; Ettorre GM; Falconi M; Ferrari G; Ferrero A; Filauro M; Giardino A; Grazi GL; Gruttadauria S; Izbicki JR; Jovine E; Katz M; Keck T; Khatkov I; Kiguchi G; Kooby D; Lang H; Lombardo C; Malleo G; Massani M; Mazzaferro V; Memeo R; Miao Y; Mishima K; Molino C; Nagakawa Y; Nakamura M; Nardo B; Panaro F; Pasquali C; Perrone V; Rangelova E; Liu R; Romagnoli R; Romito R; Rosso E; Schulick R; Siriwardena A; Spampinato MG; Strobel O; Testini M; Troisi RI; Uzunoglo FG; Valente R; Veneroni L; Zerbi A; Vicente E; Vistoli F; Vivarelli M; Wakabayashi G; Zanus G; Zureikat A; Zyromski NJ; Coppola R; D'Andrea V; Davide J; Dervenis C; Frigerio I; Konlon KC; Michelassi F; Montorsi M; Nealon W; Portolani N; Sousa Silva D; Bozzi G; Ferrari V; Trivella MG; Cameron J; Clavien PA; Asbun HJ;
Ann Surg; 2024 Jul; 280(1):56-65. PubMed ID: 38407228
[TBL] [Abstract][Full Text] [Related]
31. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
[TBL] [Abstract][Full Text] [Related]
33. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
[TBL] [Abstract][Full Text] [Related]
34. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
35. Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria.
Anger F; Döring A; van Dam J; Lock JF; Klein I; Bittrich M; Germer CT; Wiegering A; Kunzmann V; van Eijck C; Löb S
Ann Surg Oncol; 2021 Apr; 28(4):2325-2336. PubMed ID: 32920720
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study.
Secanella L; Busquets J; Peláez N; Sorribas M; Laquente B; Ruiz S; Carnaval T; Videla S; Fabregat J
Medicine (Baltimore); 2022 Dec; 101(48):e32126. PubMed ID: 36482640
[TBL] [Abstract][Full Text] [Related]
37. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
38. Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Hamad A; Crossnohere N; Ejaz A; Tsung A; Pawlik TM; Sarna A; Santry H; Wills C; Cloyd JM
Pancreas; 2022 Jul; 51(6):657-662. PubMed ID: 36099500
[TBL] [Abstract][Full Text] [Related]
39. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
40. Treatment of borderline resectable pancreatic cancer.
Cooper AB; Tzeng CW; Katz MH
Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
